Lung cancer remains a leading cause of cancer death globally, with a significant rise in cases among non-smokers attributed ...
Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) ...
Estimated geographical and temporal distribution of lung-cancer incidence varied across the four main subtypes worldwide. Our ...
A new pilot cohort study linked immune checkpoint inhibitors with a reduction in actinic keratoses in patients undergoing ...
A recent study published in The Lancet Respiratory Medicine revealed an increase in lung cancer cases among non-smokers, ...
to estimate national-level lung cancer cases for four subtypes -- adenocarcinoma, squamous cell carcinoma, small- and large-cell carcinoma. They found that adenocarcinoma -- a cancer that starts ...
A multilevel, navigation-based intervention led to more timely initiation of postoperative radiation therapy vs. usual ...
New Delhi: Drug major Glenmark Pharmaceutical has got the go-ahead from the Subject Expert Committee (SEC) functional under ...
and doublet chemotherapy as first-line treatment for patients with advanced or metastatic non-squamous non-small cell lung cancer (1L NSCLC). Mature data from patients with a minimum follow-up of 22 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback